TY - JOUR
T1 - Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission
T2 - a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
AU - Giebel, Sebastian
AU - Marks, David I.
AU - Boissel, Nicolas
AU - Baron, Frederic
AU - Chiaretti, Sabina
AU - Ciceri, Fabio
AU - Cornelissen, Jan J.
AU - Doubek, Michael
AU - Esteve, Jordi
AU - Fielding, Adele
AU - Foa, Robin
AU - Gorin, Norbert Claude
AU - Gökbuget, Nicola
AU - Hallböök, Helene
AU - Hoelzer, Dieter
AU - Paravichnikova, Elena
AU - Ribera, Josep Maria
AU - Savani, Bipin
AU - Rijneveld, Anita W.
AU - Schmid, Christoph
AU - Wartiovaara-Kautto, Ulla
AU - Mohty, Mohamad
AU - Nagler, Arnon
AU - Dombret, Hervé
N1 - Publisher Copyright:
© 2018, Springer Nature Limited.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the level of minimal residual disease is the most commonly accepted factor indicating the need for alloHSCT. In this consensus paper on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize available evidence and reflect current clinical practice in major European study groups regarding both indications for HSCT and particular aspects of the procedure including the choice of donor, source of stem cells and conditioning. Finally, we propose recommendations for daily clinical practice as well as for planning of prospective trials.
AB - Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the level of minimal residual disease is the most commonly accepted factor indicating the need for alloHSCT. In this consensus paper on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize available evidence and reflect current clinical practice in major European study groups regarding both indications for HSCT and particular aspects of the procedure including the choice of donor, source of stem cells and conditioning. Finally, we propose recommendations for daily clinical practice as well as for planning of prospective trials.
UR - http://www.scopus.com/inward/record.url?scp=85055972429&partnerID=8YFLogxK
U2 - 10.1038/s41409-018-0373-4
DO - 10.1038/s41409-018-0373-4
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 30385870
AN - SCOPUS:85055972429
SN - 0268-3369
VL - 54
SP - 798
EP - 809
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 6
ER -